Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Optilume BPH Catheter System in Benign Prostatic Hyperplasia (BPH)

NCT: NCT05567666 · COMPLETED

NCT IDNCT05567666
StatusCOMPLETED
Start Date2023-03-07
Completion2025-09-05
SponsorDean Elterman (OTHER)
First posted
Last updated

Brief Summary

A post-marketing study using Optilume Catheter System for benign prostatic hyperplasia.

Frequently Asked Questions

What is Optilume BPH Catheter System in Benign Prostatic Hyperplasia (BPH)?

Optilume BPH Catheter System in Benign Prostatic Hyperplasia (BPH) is a clinical trial registered under NCT05567666. Current status: COMPLETED.

What is the status of NCT05567666?

The current status of NCT05567666 (Optilume BPH Catheter System in Benign Prostatic Hyperplasia (BPH)) is: COMPLETED.

When did Optilume BPH Catheter System in Benign Prostatic Hyperplasia (BPH) start?

Optilume BPH Catheter System in Benign Prostatic Hyperplasia (BPH) started on 2023-03-07.

Related Devices

PMA P220029Drug coated prostatic dilation catheter for benign prostatic hyperplasiaUrotronic, Inc. PMA P010055System, hyperthermia, rf/microwave (benign prostatic hyperplasia),thermotherapyProstalund AB PMA P030006System, hyperthermia, rf/microwave (benign prostatic hyperplasia),thermotherapyMedifocus, Inc.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑